# **SheppardMullin**

# Press Releases

# Sheppard Mullin Advises Datchat, MAIA Biotechnology, Signet Healthcare Partners And Others In Recent Deals

#### 05.10.2024

Sheppard Mullin's Corporate practice has closed several transactions recently:

#### Financings

Represented New York-based private equity firm Signet Healthcare Partners in a growth investment in Curida Holding AS, a small molecules and biologics Contract Development and Manufacturing Organization specializing in the use of blow-fill-seal and nasal spray technologies, as well as antibody manufacturing. The deal was led by partner Shon Glusky. (April 16)

#### **Public Offerings**

- Advised Alta Global Group Limited (NYSE American: MMA), a technology company that enables the global martial arts and combat sports industry to maximize the monetization opportunities available to the sector, in connection with its \$6.5 million initial public offering. The deal was led by partner Jeffrey Fessler and associate Seth Lemings. (March 27)
- Represented the Underwriter in connection with Bullfrog AI Holdings Inc.'s \$6.5 million public offering of Common Shares, Pre-Funded Warrants and Warrants. Bullfrog AI Holdings (NASDAQ:BFRG; BFRGW) is a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics. The deal was led by partners Richard Friedman and Stephen Cohen and associate Emily Mastoloni. (February 5)
- Advised the Underwriter in connection with Calidi Biotherapeutics, Inc.'s \$6.1 million public offering of Common Stock, Pre-Funded Warrants and Warrants. The deal team included partners Richard Friedman and Stephen Cohen and associate Emily Mastoloni. (April 16)
- Represented the Underwriter in connection with CDT Environmental Technology Investment Holdings Limited's \$6.0 million initial public offering of Ordinary Shares. The transaction was led by partners Richard Friedman and Stephen Cohen, special counsel Yuanmei Lu and associate Hannah Zelcer. (April 17)
- Advised Datchat, Inc. (Nasdaq: DATS), a secure messaging, social media and metaverse company, in connection with its \$1.8 million public offering of Common Stock. The deal was led by partner Richard Friedman, special counsel Gregory Carney and associate Hannah Zelcer. (January 19)

#### **Private Offerings**

Advised ai, Inc. (NASDAQ: GXAI), a company developing AI applications across various sectors, in connection with its private placement offering of Common Stock and Warrants for an aggregate proceeds of \$3.5 million.

The deal was led by partner Richard Friedman and associate Hannah Zelcer. (March 15)

Represented MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, in connection with i) a private placement offering of Common Stock and Warrants for aggregate proceeds of approximately \$3.7 million (March 26); ii) a \$4.95 million at-the-market offering of Common Shares (March 25); and iii) a \$1.445 million at-the-market offering of Common Shares (February 14). The transactions were led by partner Richard Friedman, special counsel Gregory Carney and associate Hannah Zelcer.

#### Strategy

Representing **Corporate Universe, Inc.**, a holding company engaged in the energy sector, in its exploration of strategic alternatives to maximize shareholder value of its wholly-owned subsidiary, Carbon-Ion Energy, Inc., a leading innovator in super capacitors for grid scale energy storage applications. Through Carbon-ion Energy, Inc., Corporate Universe is developing a new class of energy storage device with considerable functional improvements over commercially available supercapacitors. The deal team includes partner Richard Friedman and special counsel Gregory Carney. (April 22)

### **Attorneys**

Greg R. Carney Stephen A. Cohen Jeffrey J. Fessler Richard A. Friedman Shon E. Glusky Seth A. Lemings Yuanmei Lu Emily Mastoloni Hannah Zelcer

## **Practice Areas**

**Capital Markets** 

Corporate

**Private Equity** 

### Industries

Energy, Infrastructure and Project Finance

Life Sciences